Management of Hypertrophic Cardiomyopathy

Diuretic Use in HCM

The American College of Cardiology recommends that diuretics must be used with extreme caution in patients with hypertrophic cardiomyopathy, particularly those with left ventricular outflow tract obstruction, as they can precipitate dangerous hemodynamic deterioration through volume depletion that worsens the dynamic obstruction 1, 2, 3
Diuretics should be used judiciously in patients with outflow tract obstruction at rest or with provocation, as volume depletion can trigger increased outflow obstruction and precipitate pulmonary edema 1, 2, 3
High-dose diuretics are particularly problematic and should be avoided in asymptomatic patients with resting or provocable LVOT obstruction 1
If diuretics are necessary for symptomatic relief in patients with pulmonary congestion, they may be effective but must be used cautiously and at low doses only 1, 2, 3, 4
The 2024 AHA/ACC guideline states that cautious use of low-dose oral diuretics may be considered only when persistent dyspnea with clinical evidence of volume overload and high left-sided filling pressures persists despite other guideline-directed management 4

The American College of Cardiology recommends beta blockers as the mainstay and first-line pharmacologic therapy for HCM, which work through negative inotropic effects and heart rate reduction, prolonging diastolic filling and improving symptoms 1, 2, 4
Beta blockers should be titrated to achieve a resting heart rate below 60-65 bpm 4, 5

Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) are recommended alternatives when beta blockers are ineffective or not tolerated 1, 2, 4
These agents should be used cautiously in patients with severe outflow tract obstruction, elevated pulmonary artery wedge pressure, and low systemic blood pressure, as blood pressure reduction may trigger increased outflow obstruction 1, 2
Verapamil is potentially harmful in patients with severe dyspnea at rest, hypotension, very high resting gradients, and all children <6 weeks of age 4
Dihydropyridine calcium channel blockers (e.g., nifedipine) should NOT be used in patients with obstructive physiology because their vasodilatory effects aggravate outflow obstruction 1, 2, 3

Vasodilators (ACE inhibitors, ARBs, dihydropyridine calcium channel blockers) should be discontinued as they worsen outflow tract obstruction 4, 5, 6
Digoxin is potentially harmful in HCM patients without atrial fibrillation 6, 7
Never combine beta blockers with verapamil or diltiazem due to risk of high-grade atrioventricular block 1, 2, 5, 6

Beta‑blockers lower heart rate, prolong diastolic filling, and reduce myocardial oxygen demand, improving ventricular filling and relieving ischemia, but they do not induce regression of myocardial hypertrophy. 8
Through negative inotropic action, beta‑blockers decrease left‑ventricular outflow‑tract (LVOT) gradients and relieve dynamic obstruction, yet septal wall thickness remains unchanged. 8

The ACC/AHA guideline assigns a Class I recommendation to beta‑blockers as first‑line pharmacologic therapy for symptomatic HOCM, aiming to alleviate dyspnea, angina, and chest discomfort via hemodynamic modulation. [9][8]
Guideline statements and high‑quality studies explicitly note that septal thickness reduction is not an expected outcome of beta‑blocker therapy. [9][8]

Initiate beta‑blockers in all symptomatic HOCM patients and titrate to a resting heart rate < 60–65 bpm to achieve optimal hemodynamic control. 8

If symptoms remain despite adequate beta‑blockade, add disopyramide (monitoring QT interval) or substitute with verapamil/diltiazem when beta‑blockers are intolerable. [9][8]

In patients with severe, drug‑refractory symptoms and significant LVOT obstruction despite optimal beta‑blockade, refer for septal reduction therapy (surgical myectomy preferred in younger patients with marked hypertrophy). 9

Expectation of structural remodeling (decrease in septal thickness) with beta‑blockers is a misconception; their benefit is confined to hemodynamic improvement and symptom relief. 8

Septal reduction (surgical myectomy or alcohol septal ablation) is indicated only for patients with severe, refractory symptoms after maximal beta‑blocker therapy (target HR < 60–65 bpm). It physically reduces septal mass and relieves obstruction. [9][8]
Septal reduction should not be performed in asymptomatic individuals, irrespective of the magnitude of LVOT gradient. 9